OBIO Orchestra BioMed Holdings Inc

$OBIO very interesting business model its like a biotech but with less risk with the Medtronic backing.

$OBIO - Piper Sandler reiterated an Overweight rating and $12.00 price target on Orchestra BioMed Inc get in early plenty of positive catalysts in 2027.

$OBIO held support well on the daily looking to break resistance at 6.30. Next legs 6.50, 7, 7.25, 7.90, and 8.87

Piper Sandler reiterated $OBIO Overweight-$12 and said -- We wanted to highlight OBIO as a name that could drive significant value creation for shareholders in the coming quarters. $MDT LGND TRUMY $CVRX BSX Piper Sandler added—Its key AVIM therapy to treat hypertension patients recently completed enrollment in its pivotal trial, with a data release in Q2'27 (likely HRS). If positive, which we believe it will be, it could lead to approval for this unique therapy in early '28 (though we believe the stock will move on the data). AVIM revenue (global) to OBIO could amount to $37M in '28 revenue and potentially $130M in '30. With little operating expenses associated with the model, EBIT could be $68M by the end of the decade. For MDT, AVIM could allow them to charge significantly more for their pacemakers and potentially contribute ~70 bps or more to top-line growth in the coming years. We believe investors should start to look at and build positions in OBIO. Reiterate OW.

$OBIO exceeds its BACKBEAT trial enrollment target, randomizing 330 patients versus the 316 goal.

$OBIO Held the MA9 on the daily at 5.71. It went to test and bounced right back up with strength. If you have questions about these terms, then I can help change your life because mine already has changed. A wise man once said "once you see it, you can't ever not see it."